Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH MEDIA
GLOBETECH PUBLISHING LLC

New Kit Enables Rapid PCR on Whole Blood Samples

By BiotechDaily International staff writers
Posted on 02 Dec 2013
A new kit is now available that allows biotech and other life science researchers to easily perform PCR (polymerase chain reaction) analyses on whole blood samples.

The Bioline (London, United Kingdom) MyTaq Blood-PCR Kit was specifically engineered to overcome PCR inhibitors typically present in blood samples such as anticoagulants (EDTA, citrate, and heparin) and to give significantly increased sensitivity and success rates even with demanding applications such as GC-rich templates or longer amplicons.

The MyTaq Blood-PCR Kit enables very fast and highly specific direct PCR from a wide range of human and animal whole blood samples. Its novel buffer system eliminates the need for complicated extraction or purification steps or use of additives.

The advanced formulation of the MyTaq Blood-PCR Kit allows fast cycling conditions to be used, without compromising PCR specificity or yield. The addition of an inert red dye in the mix also helps improve throughput. The kit's speed and high specificity make it ideal for multiplex PCR and high-throughput genotyping assays.

Marco Calzavara, president of Bioline, said, "With MyTaq Blood-PCR Kit, researchers can now quickly and easily achieve the purity and yield necessary for high-performance PCR direct from mammalian blood samples. This makes MyTaq Blood-PCR Kit the perfect complement to our widely used PCR reagents.”

Bioline is a wholly owned subsidiary of Meridian Life Science, Inc. (Cincinnati, OH, USA).

Richard L. Eberly, president of Meridian Life Science, Inc., said, "We are delighted to release the MyTaq Blood-PCR Kit which simplifies the process of PCR extractions from whole blood samples. We are committed to our life science customers and to bringing innovation and quality products; such as the MyTaq Blood-PCR Kits to the research laboratory, clinical diagnostic laboratories, and biotechnology companies."

Related Links:

Bioline
Meridian Life Science, Inc.



Channels

Genomics/Proteomics

view channel
Image: Pulsed near infrared light (shown in red) is shone onto a tumor (shown in white) that is encased in blood vessels. The tumor is imaged by photoacoustic tomography via the ultrasound emission (shown in blue) from the gold nanotubes (Photo courtesy of Jing Claussen (iThera Medical, Germany)).

Gold Nanotubes Are Novel Agents for Cancer Diagnosis and Treatment

Cancer researchers have produced a highly defined class of gold nanotubes that are suitable for use in animals as in vivo imaging nanoprobes, photothermal conversion agents, and drug delivery vehicles.... Read more

Drug Discovery

view channel
Image: Molecular model of the protein Saposin C (Photo courtesy of Wikimedia Commons).

Nanovesicles Kill Human Lung Cancer Cells in Culture and in a Mouse Xenograft Model

Nanovesicles assembled from the protein Saposin C (SapC) and the phospholipid dioleoylphosphatidylserine (DOPS) were shown to be potent inhibitors of lung cancer cells in culture and in a mouse xenograft model.... Read more

Biochemistry

view channel

Possible New Target Found for Treating Brain Inflammation

Scientists have identified an enzyme that produces a class of inflammatory lipid molecules in the brain. Abnormally high levels of these molecules appear to cause a rare inherited eurodegenerative disorder, and that disorder now may be treatable if researchers can develop suitable drug candidates that suppress this enzyme.... Read more

Business

view channel

Roche Acquires Signature Diagnostics to Advance Translational Research

Roche (Basel, Switzerland) will advance translational research for next generation sequencing (NGS) diagnostics by leveraging the unique expertise of Signature Diagnostics AG (Potsdam, Germany) in biobanks and development of novel NGS diagnostic assays. Signature Diagnostics is a privately held translational oncology... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.